Dogwood Therapeutics, Inc. posted a shareholder letter on March 26, 2026, detailing Q1 2026 progress including recruitment of 145 patients in the Halneuron Phase 2b HALT-CINP study, $12.5 million capital raise, IND filing for SP16 IV, and upcoming milestones like full recruitment this summer and Phase 3 plans by year-end.
Key takeaways
Recruited 145 patients in Halneuron Phase 2b HALT-CINP study with data projected for fall 2026
Raised $12.5 million in capital providing runway through Halneuron HALT-CINP data release
Filed IND for SP16 IV with royalty-free global license; Phase 1b study fully funded by National Cancer Institute
Continued development of synthesized Halneuron formulation to reduce costs
Target milestones: SP16 IND filing Q1 2026, SP16 Phase 1b dosing mid-2026, Halneuron full recruitment summer 2026, end-of-Phase 2 submission end of 2026